Synchronous liver metastases in patients with rectal cancer:can we establish which treatment first? by Pfeiffer, Per et al.
Syddansk Universitet
Synchronous liver metastases in patients with rectal cancer
can we establish which treatment first?
Pfeiffer, Per; Gruenberger, Thomas; Glynne-Jones, Robert
Published in:
Therapeutic Advances in Medical Oncology
DOI:
10.1177/1758835918787993
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC
Citation for pulished version (APA):
Pfeiffer, P., Gruenberger, T., & Glynne-Jones, R. (2018). Synchronous liver metastases in patients with rectal
cancer: can we establish which treatment first? Therapeutic Advances in Medical Oncology, 10. DOI:
10.1177/1758835918787993
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 20. Sep. 2018
https://doi.org/10.1177/1758835918787993 
https://doi.org/10.1177/1758835918787993
Therapeutic Advances in Medical Oncology
journals.sagepub.com/home/tam 1
Ther Adv Med Oncol
2018, Vol. 10: 1 –10
DOI: 10.1177/ 
1758835918787993
© The Author(s), 2018.  
Reprints and permissions:  
http://www.sagepub.co.uk/
journalsPermissions.nav
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Colorectal cancer (CRC) affects nearly 1.4 mil-
lion new patients each year worldwide.1 The 
treatment algorithm for local or locally advanced 
colon and rectal cancer (RC), and also for patients 
with never-resectable metastases, is well estab-
lished.2–4 However, the optimal strategy in 
patients with synchronous metastasis is more 
controversial and, especially in patients with RC, 
several modalities must be combined to achieve 
the most favorable outcome. Before the introduc-
tion of total mesorectal excision (TME) a local 
recurrence was frequently seen in 30–40% of 
patients with locally advanced RC.5 Neoadjuvant 
long-course chemo-radiation (LC-CRT) or 
short-course radiotherapy (SC-RT) followed by 
appropriate TME has reduced local recurrence 
(LR) rates to 5% or even less as shown not only in 
randomized trial with selected patients but also in 
population cohorts.6,7 However, the role and tim-
ing of neoadjuvant radiation is less well defined in 
patients presenting with synchronous metastasis. 
Randomized studies have focused on one treat-
ment modality (e.g. preoperative LC-CRT or 
SC-RT in patients with resectable RC or chemo-
therapy in the setting of widespread nonresecta-
ble metastatic disease) but the sequence of 
different modalities (surgery, chemotherapy, and 
radiation) has not been studied in a randomized 
strategy trial. Based on lack of consensus regard-
ing the optimal sequence of surgery, systemic 
therapy and radiotherapy for patients with stage 4 
RC treated with curative intent, a ‘multidiscipli-
nary session: synchronous liver metastases in RC: 
which treatment first?’ was organized by the 
European Society for Medical Oncology (ESMO) 
and presented during the ESMO 2017 confer-
ence in Madrid, Spain. Three distinct lectures 
focused on the radiation therapy perspective, the 
surgical oncology perspective, and the medical 
oncology perspective. The present paper is a sum-
mary of those three lectures with focus on a mul-
tidisciplinary approach and with an update on 
recent literature.
All patients must be evaluated by a 
multidisciplinary team
Many strategies are possible in patients with RC 
with synchronous metastases. There are numer-
ous overviews but no randomized trial to guide us 
on the optimal strategy. A network meta-analysis 
(no phase III study) including 3605 patients with 
synchronous colorectal liver metastases (CRLM) 
demonstrated no clear statistical surgical out-
come or survival advantage toward any particular 
strategy.8 Therefore, selecting the optimal treat-
ment strategy in patients with synchronous meta-
static RC is a difficult task due to lack of good 
evidence. There are trials evaluating systemic 
therapy in patients with metastatic CRC (mCRC) 
and there are trials with radiotherapy for patients 
with localized RC but there are no trials for 
patients with both manifestations. In particular, 
there are no randomized trials to evaluate the best 
sequence of therapy and no widely accepted 
standard of treatments. Thus treatment is not evi-
dence based but mainly rests upon expert opinion 
and short-term oncological goals.
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There are at least four scenarios for the manage-
ment of patients with synchronous metastatic 
RC. In patients with resectable CRLM, the pri-
mary could be asymptomatic or symptomatic. 
Similarly, in patients with nonresectable CRLM 
the primary could also be asymptomatic or symp-
tomatic. The decision for timing of the resection 
of either the primary or the CRLM should be 
individualized for each patient, considering tech-
nical, oncological and patient factors. An alterna-
tive approach in addition to ‘liver first’ or ‘rectal 
first’ is ‘the interval strategy’ that involves the 
administration of LC-CRT followed by the 
resection of the CRLM in the interval between 
RT and rectal surgery.9,10 For these reasons, all 
patients must be evaluated by a specialist multi-
disciplinary team (MDT).
At the MDT, the following questions must be 
asked: what is the burden of metastatic disease? 
Are there other sites of metastases, and if so, are 
these extrahepatic metastases potential curable 
(e.g. a small resectable lung metastases)? There 
should be a detailed magnetic resonance imaging 
(MRI) assessment of the primary, and the perfor-
mance status and the patient’s comorbidity must 
be well known. There is a need for randomized 
controlled trials to further investigate the optimal 
treatment strategy in patients with synchronous 
metastatic RC (mRC).
Analysis of the Surveillance, Epidemiology and 
End Results database including more than 
60,000 patients from 1988 to 2010 showed that 
the majority of patients with mCRC had under-
gone primary tumor resection but beginning in 
2001, there was a trend toward fewer resec-
tions.11 Despite a declining resection rate, an 
increased overall survival (OS) was found. A 
recent individual patient data analysis of trials in 
mCRC showed an improved survival in synchro-
nous mCRC patients if the primary was 
resected.12 Such analyses are open to bias because 
the reasons that resection is not performed are 
not available. Hence, presently, it’s not known 
whether the primary should be resected or not. 
Several randomized studies like CAIRO4 are 
evaluating this problem in patients receiving pal-
liative therapy but if the overall aim is cure then 
the primary must of course be resected.
In patients with easy resectable primary and 
CRLM, perioperative FOLFOX before and after 
liver resection is the recommended treatment 
strategy, and in selected cases, the primary may be 
resected concurrently.3 Recommendations are to 
administer chemotherapy for a total of at least 6 
months.
In patients with nonresectable liver-limited 
CRLM, patients should start with best systemic 
therapy and patients should be restaged and eval-
uated by the MDT every 2 months.
The classical way of treating patients with RC 
and metastases was to start with LC-CRT and 
then resect the primary. The major problem with 
this strategy is that administration of effective 
systemic treatment is postponed for months and 
during this period, there is a risk of further pro-
gression of metastatic disease which may convert 
potential curable disease to never-resectable dis-
ease. At the ESMO consensus meeting, all par-
ticipants agreed on upfront chemotherapy in 
case of metastatic disease and asymptomatic 
primary.2
Magnitude of the problem
How many patients with RC are diagnosed with 
synchronous metastasis? In a nationwide study 
covering 98% of Swedish RC cases from 2007 to 
2011 (total 9158 patients), it was found that 20% 
of patients had mRC at the time of diagnosis, 
75% of mRC patient had synchronous liver 
metastases and one half had liver-limited disease 
(LLD). Resection rate was 23% in RC patients 
with LLD, however, with huge variation from 
8.5% to 32.1% between regions.13 Preoperative 
chemotherapy was administered to 33% of 
patients who had resection.
Efficacy of systemic therapy on colorectal 
liver metastases
According to the current ESMO consensus guide-
lines,3 a preoperative strategy with FOLFOX may 
be used in patients with good prognosis and easily 
resectable metastasis but if a conversion or down-
sizing strategy is recommended by the MDT then 
the best systemic therapy must be initiated. It is 
well known that a higher overall response rate 
(ORR) increases the chance for resection of 
CRLM14,15 and therefore a combination that 
produces the highest ORR is recommended in 
fit patients. In general, double regimens (e.g. 
FOLFOX, FOLFIRI, CapOx) compared with 
monotherapy, and triplet regimens (e.g. 
FOLFOXIRI) compared with double regimens 
produce higher ORRs.3
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When epidermal growth factor receptor 
(EGFR) inhibitors (cetuximab or panitu-
mumab) are added to combination regimens 
like FOLFIRI or FOLFOX, all efficacy param-
eters are improved (Table 1); ORRs are 
increased and progression-free survival (PFS) 
and OS are prolonged but this benefit is 
restricted to patients who are RAS wildtype and 
BRAF wildtype.16–19 A similar consistency has 
not been observed when bevacizumab was 
added to modern regimens3 and in the largest 
randomized study, bevacizumab did not 
improve ORR.20 Nevertheless, the optimal 
combination of chemotherapy and targeted 
therapy has been discussed for many years. 
Three studies have directly compared efficacy 
of EGFR inhibitors and bevacizumab in mCRC 
patients (Table 2A). In the randomized phase 
III FIRE-3,21,22 the primary endpoint, ORR, 
was not achieved but the secondary endpoint, 
OS, was significantly longer, particularly in the 
subgroup with RAS and BRAF wildtype tumors. 
In the randomized phase II PEAK study,23 
there was a significantly longer PFS and numer-
ically longer OS, but no difference in ORR. In 
CALGB 80405, double chemotherapy with 
cetuximab resulted in higher ORR but with no 
significant difference in PFS or OS.24,25 Several 
studies have shown that left-sided CRC are 
more dependent on EGFR-related pathways 
and therefore it was evident to do subgroup 
analysis in patients with left-sided tumors 
(Table 2B). Within this subgroup analysis, the 
picture became much more homogenous show-
ing higher ORR and prolonged OS in patients 
with left-sided primary (including rectal) 
treated with EGFR inhibitors compared with 
bevacizumab.26,27 In the two reviews, it was 
concluded that the preferred treatment option 
in patients with left-sided RAS and BRAF 
wildtype tumor is doublet chemotherapy with 
EGFR inhibitors.
A number of randomized studies have evaluated 
triplet chemotherapy in patients with mCRC, 
often unselected by stage and tumor biology but 
elected by younger age and excellent performance 
status (Table 3A). Two Italian phase III trials28,29 
showed that triplet chemotherapy, with or without 
bevacizumab, increased ORR and prolonged PFS 
and OS. Other studies have shown comparable 
and promising results. Bevacizumab was added to 
all combinations and we can therefore only con-
clude that triplet chemotherapy with bevacizumab 
is tolerable but the additional benefit of bevaci-
zumab cannot be evaluated from these studies. In 
the OLIVIA trial,30 in which mCRC patients with 
LLD were included, triplet chemotherapy with 
bevacizumab produced an impressing ORR of 
81% (Table 3A). Consistently, all studies evaluat-
ing triplet chemotherapy with bevacizumab pro-
duced a high ORR of at least 60%.
Table 1. Doublet chemotherapy with or without anti-EGFR in patients with RAS wild-type metastatic colorectal cancer.[16-19].
Authors (trial name) Regimen N RR
(%)
Δ %
RR
PFS
(mo)
Δ PFS 
(mo)
OS
(mo)
Δ OS 
(mo)
Van Cutsem, (CRYSTAL)
JCO 2015
FOLFIRI 189$ 39
+28
8.4
+3.0
20.2
+8.2
FOLFIRI + Cet 178$ 66* 11.4* 28.4*
Bokemeyer, (OPUS)
EJC 2015
FOLFOX 49$ 29
+28
5.8
+6.2
17.8
+2.0
FOLFOX + Cet 38$ 56* 12.0* 19.8
Douillard, (PRIME)
NEJM 2013
FOLFOX 253$ 48
+9
7.9
+2.2
20.2
+5.6
FOLFOX + Pan 259$ 57* 10.1* 25.8*
Qin, (TAILOR)
ESMO 2016
FOLFOX 200‡ 40
+21
7.4
+1.9
17.8
+2.9
FOLFOX + Cet 193‡ 61* 9.2* 20.7*
*Significant difference. 
$Retrospective evaluation of RAS status.
‡All patients were RAS wildtype at inclusion.
RR, response rate; PFS, progression-free survival; OS, overall survival; Cet, cetuximab; Pan, panitumumab.
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A number of phase II studies have combined tri-
plet chemotherapy with EGFR inhibitors, mainly 
including mCRC KRAS wildtype (Table 3B). All 
studies showed a very high ORR of more than 
70%, but the additional benefit of EGFR inhibi-
tors cannot be evaluated. The first study to evalu-
ate triplet chemotherapy with or without targeted 
therapy was presented at ESMO 2017. In a rand-
omized phase II trial, patients with RAS wildtype 
mCRC patients were randomized to modified 
FOLFOXIRI ± panitumumab.40 The authors 
found that triplet + panitumumab produced a sig-
nificant higher ORR (86% versus 61%), not only 
in left-sided tumors but also with right-sided loca-
tion. Unpredictably they also found a high ORR 
(71%) in patients with BRAF-mutated tumors.
Efficacy of systemic therapy on the primary 
cancer
ORR in patients with metastatic disease is close to 
50%3 but what is the response rate in the primary 
to systemic therapy? It is difficult to measure 
tumor shrinkage in the primary according to 
RECIST 1.1, since it arises in a hollow distensible 
organ and the longest diameter can hardly be 
defined on axial images, but regression in the pri-
mary is comparable with that seen in metastatic 
sites. However, perhaps pathological complete 
response (pCR) is a more relevant measure, since 
it is reproducible and there is an excellent correla-
tion with OS.41 After RT and delayed surgery, a 
pCR of around 10% can be expected, but this 
increases to around 15% if chemotherapy, mainly 
Table 2A. Bevacizumab or anti-EGFR in patients with RAS wild-type/BRAF wild-type metastatic colorectal cancer.[22-24]
Authors (trial name) Regimen N RR
(%)
Δ %
RR
PFS
(mo)
Δ OS 
(mo)
OS
(mo)
Δ OS 
(mo)
Stintzing (FIRE-3)
Lancet Onc 2016
FOLFIRI + Bev 201 59
+6
10.2
+0.1
25.0
+8.1
FOLFIRI + Cet 199 65 10.3 33.1*
Schwartzberg (PEAK)
JCO 2014
FOLFOX + Bev 82 61
+3
9.5
+3.5
28.9
+12.4
FOLFOX + Pan 88 64 13.0* 41.3
Venook (CALGB 
80405)
JAMA 2017
Double + Bev 256 54
+15
11.3
+0.1
31.2
+0.8
Double + Cet 270 69* 11.4 32.0
*Significant difference.
Unselected according to primary location. Results are shown as difference in efficacy to substantiate the difference in effect.
Bev, bevacizumab; Cet, cetuximab; OS, overall survival; Pan, panitumumab; PFS, progression-free survival; RR, response rate.
Table 2B. Bevacizumab or anti-EGFR in left-sided RAS wild-type/BRAF wild-type metastatic colorectal cancer.[22,23,25]
Authors (trial 
name)
Regimen N RR
(%)
Δ %
RR
PFS
(mo)
Δ OS 
(mo)
OS
(mo)
Δ OS 
(mo)
Stintzing (FIRE-3)
Lancet Onc 2016
FOLFIRI + Bev 149 62 +7 10.7 0 28.0 +10.3
FOLFIRI + Cet 157 69 10.7 38.3*
Schwartzberg 
(PEAK)
JCO 2014
FOLFOX + Bev 54 57 +7 11.5 +3.1 32.0 +11.4
FOLFOX + Pan 53 64 14.6 43.4
Venook (CALGB 
80405)
ASCO 2016
Double + Bev 152 58 +11 11.2 +1.5 32.6 +6.7
Double + Cet 173 69* 12.7 39.3*
* Significant difference
Bev, bevacizumab; Cet, cetuximab; OS, overall survival; Pan, panitumumab; PFS, progression-free survival; RR, response rate.
P Pfeiffer, T Gruenberger et al.
journals.sagepub.com/home/tam 5
Ta
bl
e 
3A
. 
R
an
do
m
iz
ed
 tr
ia
ls
 e
va
lu
at
in
g 
tr
ip
le
t c
he
m
ot
he
ra
py
 w
ith
 o
r 
w
ith
ou
t b
ev
ac
iz
um
ab
 in
 p
at
ie
nt
s 
w
ith
 m
et
as
ta
tic
 c
ol
or
ec
ta
l c
an
ce
r 
un
se
le
ct
ed
 fo
r 
R
A
S 
st
at
us
.[2
8-
33
]
Fa
lc
on
e 
(G
O
N
O
),
JC
O
 2
00
7
C
re
m
ol
in
i (
TR
IB
E)
,
A
nn
 O
nc
ol
 2
01
5
B
en
de
ll
 (S
TE
A
M
),
JC
O
 2
01
6
Sc
hm
ol
l (
C
H
A
R
TA
),
A
SC
O
 2
01
7
Fa
lc
on
e 
(M
O
M
A
),
A
nn
 O
nc
ol
 2
01
6
G
ru
en
be
rg
er
 
(O
LI
VI
A
),
A
nn
 O
nc
ol
 2
01
4
 
FO
LF
IR
I
n 
=
 1
22
TR
IP
LE
n 
=
 1
22
FO
LF
IR
I
B
ev
n 
=
 2
56
TR
IP
LE
B
ev
n 
=
 2
52
FO
LF
O
X
B
ev
n 
=
 9
5
sT
R
IP
LE
B
ev
n 
=
 9
2
cT
R
IP
LE
B
ev
n 
=
 9
3
FO
LF
O
X
B
ev
n 
=
 1
21
TR
IP
LE
B
ev
n 
=
 1
21
TR
IP
LE
B
ev
n 
=
 1
17
TR
IP
LE
B
ev
n 
=
 1
15
FO
LF
O
X
B
ev
n 
=
 3
9
TR
IP
LE
B
ev
n 
=
 4
1
A
ge
 (y
ea
rs
)
64
62
60
60
58
56
58
62
60
61
62
57
63
P
S 
0,
 %
61
%
61
%
90
%
90
%
54
%
57
%
67
%
47
%
53
%
85
%
85
%
80
%
56
%
R
R
 (%
)
41
66
*
53
65
*
47
62
60
61
70
68
58
62
81
*
P
FS
 (m
on
th
s)
6.
9
9.
8*
9.
7
12
.3
*
9.
5
11
.4
11
.9
10
.3
12
.0
9.
5
10
.6
11
.5
18
.6
O
S 
(m
on
th
s)
16
.7
22
.6
*
25
.8
29
.8
*
30
.7
28
.3
34
.0
24
.0
28
.0
–
–
–
–
* 
Si
gn
ifi
ca
nt
 d
iff
er
en
ce
cT
R
IP
LE
, c
on
tin
uo
us
 T
R
IP
LE
; O
S,
 o
ve
ra
ll 
su
rv
iv
al
; P
FS
, p
ro
gr
es
si
on
-f
re
e 
su
rv
iv
al
; P
S,
 p
er
fo
rm
an
ce
 s
ta
tu
s;
 R
R
, r
es
po
ns
e 
ra
te
; s
TR
IP
LE
, s
eq
ue
nt
ia
l T
R
IP
LE
; T
R
IP
LE
, c
om
bi
na
tio
n 
of
 
5-
fl
uo
ro
ur
ac
il,
 o
xa
lip
la
tin
, a
nd
 ir
in
ot
ec
an
.
Therapeutic Advances in Medical Oncology 10
6 journals.sagepub.com/home/tam
5- fluorouracil (5-FU), is used as a radiation sen-
sitizer. If systemic therapy is added after SC-RT 
or LC-CRT, a pCR of at least 20% can be 
achieved. Garcia-Aguilar and colleagues con-
ducted four consecutive phase II trials in patients 
with localized RC, and after LC-CRT, they added 
sequentially more and more cycles of FOLFOX 
and found that LC-CRT followed by 3 months of 
FOLFOX resulted in a pCR of 38%.42
The traditional method for treating high-risk pri-
mary RC includes the delivery of neoadjuvant 
LC-CRT followed by TME. However, the use of 
preoperative chemotherapy as an alternative has 
increased in popularity and is presently being stud-
ied in ongoing trials. Preoperative chemotherapy 
has the potential to impact on the viability of dis-
tant micrometastases early in the evolution of the 
disease, and could thereby reduce systemic fail-
ures, in addition to facilitating local control by sur-
gical resection, avoiding the long-term toxic effects 
of CRT. A number of small studies have evaluated 
pCR rate after chemotherapy without RT.43–48 
Response rate is more than 50% in all studies and 
pCR is around 15% (range from 5% to 25%). 
Perhaps even more interesting, the risk of PD is 
0%, except for one study where one patient devel-
oped PD during therapy: thus, the response to pre-
operative chemotherapy could also select patients 
for either CRT or upfront surgery, which should 
result in decreased morbidity for some patients.
These promising data may question the use of RT 
in patients with metastatic RC but until more 
solid data are available, we will recommend 
SC-RT if the strategy is with curative intent. This 
is supported by data from a Chinese randomized 
three-arm phase III including almost 500 patients 
with locally advanced RC.49 Patients were essen-
tially randomized to LC-CRT (with 5-FU), 
LC-CRT (with FOLFOX), or FOLFOX without 
RT. Preoperative FOLFOX alone resulted in 
lower pCR rate than LC-CRT (the rate of pCR 
was 14%, 28%, and 7%, respectively) but there 
was no difference in R0 resection rate (around 
90% in all three arms).
Efficacy of radiotherapy on the primary 
cancer
Classically, there are two possible choices for pre-
operative radiotherapy: SC-RT (25 Gy/5 frac-
tions) or LC-CRT (45–50.4 Gy/25–28 fractions), 
which are equally effective in resectable can-
cers.4,50–51 Preoperative RT induces pCR in 
around 15% without clear-cut difference in fre-
quency between LC-RT and SC-RT if there is a 
planned delay of 6–8 weeks before surgery to 
allow shrinkage of the primary tumor. In the 
Stockholm III trial, there was no difference in 
local recurrence rate after SC-RT or LC-RT if 
surgery was delayed in both situations.52
The short overall treatment time (OTT) of 
SC-RT, usually in 5 consecutive days with imme-
diate surgery, is a highly flexible treatment strat-
egy, which is associated with high compliance and 
low toxicity, in part reflecting an insufficient 
interval to express the normal tissue reactions and 
systemic inflammatory effects from radiation 
before the rectum is surgically removed.6,53
There are at least two questions in RC patients 
with CRLM. Do patients need radiotherapy at all 
Table 3B. Triplet chemotherapy with anti-EGFR in metastatic colorectal cancer.[34-40]
Garufi 
(POCHER),
BJC 2010
Assenat 
(FRENCH), 
Oncologist 
2011
Folprecht 
(GERMAN),
BMC Cancer 
2014
Saridaki 
(GREEK)
BJC 2012
Fornaro 
(TRIP),
Ann Oncol 
2013
Cremolini 
(MACBETH),
JAMA Oncol 2018
Geissler (VOLFI), 
Ann Oncol 2017
TRIPLE
Cet 
n = 43
TRIPLE
Cet 
n = 42
TRIPLE
Cet 
n = 20
TRIPLE
Cet 
n = 30
TRIPLE
Pan
n = 37
TRIPLE
Cet 
n = 59
TRIPLE
Cet
n = 57
TRIPLE
n = 33
TRIPLE
Pan
n = 63
RR (%) 79 81 75 70 89 68 75 61 86*
PFS (months) 14 9.5 16 10.2 11.3 11.2 9.3 10.5 10.8
OS (months) 37 24.7 33 30.3 – – – – –
* Significant difference
Cet, cetuximab; OS, overall survival; Pan, panitumumab; PFS, progression-free survival; RR, response rate; TRIPLE, combination of 5-fluorouracil, 
oxaliplatin, and irinotecan.
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and if so, which out of SC-RT or LC-CRT? 
Findings from a pooled analysis of individual 
patient data from several institutions41 showed 
that patients who obtained a pCR after preopera-
tive LC-CRT had a significantly longer OS than 
those with residual disease and this may be an 
argument for recommendation of RT even in 
patients with synchronous mRC.
Is there a role for radiotherapy to the 
primary tumor in patients with resectable 
stage IV rectal cancer?
Patients are unlikely to be cured without surgery 
and patients are less likely to be cured without 
chemotherapy. Radiotherapy has only a minor 
impact on curability, but so far, RT is indicated if 
the plan is to resect metastases and the primary. 
Otherwise, RT is only indicated in the case of pal-
liation of symptoms. In a phase II study in patients 
with near-obstruction lesions, SC-RT and chem-
otherapy allowed most patients to avoid surgery 
even those with near-obstruction lesions.54 In the 
RAPIDO trial, patients with ‘high-risk RC’ were 
randomized to standard LC-CRT or SC-RT fol-
lowed by 6 cycles of CapOx before TME.55 
Unfortunately, results from the RAPIDO trial 
will not be available until 2020.
What is the downside of radiotherapy? LC-CRT 
may delay the application of full doses of chemo-
therapy or worsen the compliance to systemic 
doses of chemotherapy. However, SC-RT can be 
administered between full doses of systemic ther-
apy with no or only minimal delay of administra-
tion. SC-RT combined with systemic therapy has 
primarily been used in Europe but the first US 
experience with SC-RT as part of the multidisci-
plinary management of mRC has recently been 
reported with promising results.56
Timing of resection of the liver metastasis 
and the rectal cancer
If a patient presents either with resectable liver 
metastasis or is converted to resectable disease 
after systemic therapy, the timing of liver resec-
tion is more crucial than the resection of the pri-
mary. We have learned throughout the last 15 
years that patients should get their resection of 
liver metastasis as soon as possible after evaluat-
ing the benefit of systemic therapy. Interestingly, 
the more aggressive/effective the therapy is, the 
faster a resection can be offered. In the back-
ground is the fact that the remaining liver after 
resection has to recover and function quickly 
especially after major hepatectomy. Evaluable 
literature clearly demonstrates that length of 
chemotherapy correlates with morbidity and 
mortality after liver resection.57 In the only pro-
spective international trial evaluating the sys-
temic therapy potential to convert unresectable 
LLD into resectable disease, two patients died 
due to liver failure after receiving more than 6 
months of treatment.30 We therefore advocate 
repeat MDT discussions every 2 months to iden-
tify resectable patients as soon as possible.
Timing of resection of the rectal primary is crucial 
on two points: first, the best waiting period on 
maximum local remission after RT or CRT in 
resectable RC and second, the best downsizing 
therapy prior to potential curative resection in ini-
tially locally advanced noncurable resectable 
disease.
Conclusion
The optimal sequence and use of the individual 
modalities remain undefined, but should be 
employed on an individual basis. Multidisciplinary 
approach and decision making are essential in 
patients with RC and synchronous metastases. In 
the MDT, the treatment aim must be defined 
upfront and there should be a regular follow up 
with re-evaluation and rediscussion every 2 
months.
Unless the primary and the few liver metastases 
are ‘easily resectable’, we recommend begin-
ning with the most effective systemic chemo-
therapy (often triplet chemotherapy with 
targeted therapy, depending on RAS status) 
with re-evaluation at the MDT every 2 months. 
We also recommend liver surgery first as soon 
as CRLM becomes resectable and to continue 
systemic treatment before (and perhaps after) 
resection of the primary for a total of at least 6 
months. SC-RT can be added to systemic 
chemotherapy at virtually any point with no or 
minimal delay.
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